Zydus, MSN partner to Launch First Generic of Adempas® (Riociguat Tablets) in the U.S.

approvedAdempasPositive

AI Analysis

Summary

Zydus Lifesciences and MSN announced the first-to-market generic launch of Adempas (riociguat) in the U.S., providing a lower-cost option for patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Outcome Details

First-to-market generic launch of riociguat in the U.S.

Importance:6/10

Sentiment:

0.70

generic_launchpartnershippulmonary_hypertensionfirst-to-market

Related Companies

$TRAX

Read the original article

Published by PR Newswire Biotech on October 5, 2026 4:41 PM

Read Original